EU External Trade - Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale, Other

Extra-EU sourcing of Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale, Other is highly concentrated. 🇨🇭 Switzerland captures 39.6% of imports (€69.3B), followed by 🇺🇸 United States (29.5%). With an HHI of 2632, this Concentrated market exposes the EU to supply dependency risks.

The main extra-EU export markets for Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale, Other are 🇨🇭 Switzerland, 🇺🇸 United States, 🇬🇧 United Kingdom. 🇨🇭 Switzerland absorbs 27.0% of European exports (€138.4B).

Within the EU, the leading importers of Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale, Other are 🇧🇪 Belgium, 🇸🇮 Slovenia, 🇩🇪 Germany. 🇧🇪 Belgium accounts for 20.3% of EU imports.

In 2025, imports were rising (12.5%) and exports rising (6.9%) compared to the previous year.